$RZLT
Rezolute, Inc. Stock $rzlt

$rzlt Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000114420418008930 Filed on February 14, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2016 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.390M	$2.200M	$1.730M
YoY Change	29.19%	27.17%	16.11%
% of Gross Profit
Research & Development	$2.496M	$3.413M	$3.075M
YoY Change	-27.42%	10.98%	21.85%
% of Gross Profit
Depreciation & Amortization	$266.8K	$266.8K	$278.1K
YoY Change	-5.67%	-4.06%	85.11%
% of Gross Profit
Operating Expenses	$2.496M	$5.751M	$4.889M
YoY Change	-53.69%	17.62%	20.23%
Operating Profit	-$4.953M	-$5.751M	-$4.889M
YoY Change	-8.11%	17.62%	20.23%
Interest Expense	$53.36K	$147.00	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$14.35K	$32.37K	$1.313K
YoY Change	-335.39%	2365.42%	141.8%
Pretax Income	-$4.970M	-$5.720M	-$4.890M
YoY Change	-7.62%	16.97%	20.15%
Income Tax
% Of Pretax Income
Net Earnings	-$4.968M	-$5.719M	-$4.888M
YoY Change	-7.74%	16.99%	20.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$4.602M	-$5.296M	-$5.963M
COMMON SHARES
Basic Shares Outstanding	54.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q4	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$80.00K	$870.0K	$3.570M
YoY Change	-98.2%	-75.63%	108.77%
Cash & Equivalents	$80.00K	$870.0K	$3.570M
Short-Term Investments
Other Short-Term Assets	$370.0K	$295.7K	$213.4K
YoY Change	-9.76%	38.55%	64.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$450.0K	$1.164M	$3.787M
YoY Change	-90.72%	-69.27%	105.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.530M	$4.798M	$5.729M
YoY Change	-17.03%	-16.25%	-5.62%
Goodwill
YoY Change
Intangibles		$40.68K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$130.0K	$320.0K	$380.0K
YoY Change	105.59%	-15.79%	-32.14%
Total Long-Term Assets	$4.690M	$5.158M	$6.152M
YoY Change	-21.12%	-16.16%	-8.04%
TOTAL ASSETS
Total Short-Term Assets	$450.0K	$1.164M	$3.787M
Total Long-Term Assets	$4.690M	$5.158M	$6.152M
Total Assets	$5.140M	$6.321M	$9.938M
YoY Change	-52.39%	-36.39%	16.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.210M	$2.120M	$1.530M
YoY Change	69.84%	38.56%	-31.08%
Accrued Expenses	$20.00K	$0.00	$0.00
YoY Change			-100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$920.0K	$10.00K	$10.00K
YoY Change	9100.0%	0.0%	-83.33%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$4.370M	$2.251M	$1.670M
YoY Change	116.32%	34.79%	-32.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$240.0K	$243.7K	$340.0K
YoY Change	-23.73%	-28.33%	-26.09%
Total Long-Term Liabilities	$240.0K	$268.7K	$340.0K
YoY Change	-23.73%	-20.96%	-26.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.370M	$2.251M	$1.670M
Total Long-Term Liabilities	$240.0K	$268.7K	$340.0K
Total Liabilities	$4.610M	$2.520M	$2.010M
YoY Change	97.44%	25.36%	-31.93%
SHAREHOLDERS EQUITY
Retained Earnings		-$76.73M	-$52.75M
YoY Change		45.45%	44.66%
Common Stock			$40.95K
YoY Change			68.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$532.9K	$3.802M	$7.933M
YoY Change
Total Liabilities & Shareholders Equity	$5.140M	$6.320M	$9.938M
YoY Change	-52.39%	-36.41%	16.45%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2016 Q4
OPERATING ACTIVITIES
Net Income	-$4.968M	-$5.719M	-$4.888M
YoY Change	-7.74%	16.99%	20.21%
Depreciation, Depletion And Amortization	$266.8K	$266.8K	$278.1K
YoY Change	-5.67%	-4.06%	85.11%
Cash From Operating Activities	-$2.180M	-$3.140M	-$3.090M
YoY Change	-39.61%	1.62%	34.93%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$140.0K
YoY Change	-100.0%	-100.0%	-79.41%
Acquisitions
YoY Change
Other Investing Activities	$190.0K	$0.00	$120.0K
YoY Change		-100.0%	-73.33%
Cash From Investing Activities	$190.0K	$0.00	-$30.00K
YoY Change	-1050.0%	-100.0%	-86.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.200M	0.000	3.330M
YoY Change	-73.33%	-100.0%	78.07%
NET CHANGE
Cash From Operating Activities	-2.180M	-3.140M	-3.090M
Cash From Investing Activities	190.0K	0.000	-30.00K
Cash From Financing Activities	1.200M	0.000	3.330M
Net Change In Cash	-790.0K	-3.140M	210.0K
YoY Change	-190.8%	-1595.24%	-132.31%
FREE CASH FLOW
Cash From Operating Activities	-$2.180M	-$3.140M	-$3.090M
Capital Expenditures	$0.00	$0.00	-$140.0K
Free Cash Flow	-$2.180M	-$3.140M	-$2.950M
YoY Change	-39.11%	6.44%	83.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	244341	USD
CY2017Q2	us-gaap	Interest Payable Current InterestPayableCurrent	2762	USD
CY2017Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	588	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1771322	USD
CY2017Q4	us-gaap	Assets Assets	6321470	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2701728	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	535303	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4440000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3646	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3646	USD
	us-gaap	Depreciation Depreciation	546429	USD
	us-gaap	Depreciation Depreciation	533394	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2125966	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2701728	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6058955	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8052651	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-488865	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-3618467	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5655177	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4440000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85087	USD
	rzlt	Warrant Expense WarrantExpense	0	USD
	rzlt	Warrant Expense WarrantExpense	535303	USD
CY2016Q2	us-gaap	Cash Cash	4062013	USD
CY2016Q4	us-gaap	Professional Fees ProfessionalFees	139865	USD
CY2017Q4	us-gaap	Professional Fees ProfessionalFees	213399	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	4889244	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	5750958	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4889244	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5750958	USD
CY2016Q4	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	1313	USD
CY2017Q4	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	156	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1313	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-4887931	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-5718587	USD
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2017Q4	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	31838	USD
CY2016Q4	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	0	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	304575	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001509261
	dei	Entity Registrant Name EntityRegistrantName	Rezolute, Inc.
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	40676	USD
	dei	Trading Symbol TradingSymbol	RZLT
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54073309	shares
CY2017Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44322	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2762	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	90	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2250940	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	1163799	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	268732	USD
CY2016Q4	rzlt	Compensation And Benefits For Research And Development CompensationAndBenefitsForResearchAndDevelopment	1909518	USD
CY2017Q4	rzlt	Compensation And Benefits For Research And Development CompensationAndBenefitsForResearchAndDevelopment	1482946	USD
CY2017Q4	rzlt	Investor Relations InvestorRelations	133705	USD
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32371	USD
CY2017Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	244341	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4797823	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	4928553	USD
CY2017Q2	us-gaap	Other Assets Current OtherAssetsCurrent	442015	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76725162	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64321962	USD
CY2017Q4	rzlt	Consultants And Outside Costs ConsultantsAndOutsideCosts	233798	USD
CY2017Q4	us-gaap	Manufacturing Costs ManufacturingCosts	227602	USD
CY2017Q2	us-gaap	Cash Cash	4486538	USD
CY2017Q4	us-gaap	Cash Cash	868071	USD
CY2016Q4	rzlt	Compensation And Benefits For General And Administrative CompensationAndBenefitsForGeneralAndAdministrative	1285052	USD
CY2017Q4	us-gaap	Deferred Costs Leasing Net Noncurrent DeferredCostsLeasingNetNoncurrent	74831	USD
CY2017Q2	us-gaap	Deferred Costs Leasing Net Noncurrent DeferredCostsLeasingNetNoncurrent	86293	USD
CY2017Q4	us-gaap	Deposits Deposits	25046	USD
CY2017Q2	us-gaap	Deposits Deposits	25046	USD
CY2017Q4	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	318272	USD
CY2016Q4	rzlt	Consultants And Outside Costs ConsultantsAndOutsideCosts	194783	USD
CY2016Q4	us-gaap	Manufacturing Costs ManufacturingCosts	567430	USD
CY2016Q4	rzlt	Investor Relations InvestorRelations	87428	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	243686	USD
CY2017Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	329621	USD
CY2017Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	10000	USD
CY2017Q2	us-gaap	Assets Assets	10628910	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	295728	USD
CY2017Q4	rzlt	Compensation And Benefits For General And Administrative CompensationAndBenefitsForGeneralAndAdministrative	1672494	USD
CY2017Q4	us-gaap	Interest Expense InterestExpense	147	USD
CY2017Q4	rzlt	Facilities And Other Costs FacilitiesAndOtherCosts	479149	USD
CY2016Q4	rzlt	Facilities And Other Costs FacilitiesAndOtherCosts	403648	USD
CY2017Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53762358	shares
CY2016Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40788241	shares
CY2016Q4	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	0	USD
CY2017Q4	us-gaap	License Costs LicenseCosts	407605	USD
CY2016Q4	us-gaap	License Costs LicenseCosts	0	USD
CY2016Q4	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	301520	USD
CY2016Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2017Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	524	USD
CY2016Q4	us-gaap	Interest Expense InterestExpense	0	USD
CY2017Q4	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	581988	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1986127	USD
CY2016Q4	us-gaap	Cash Cash	3573148	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	272587	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	5816	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5816	USD
	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	0	USD
	us-gaap	Payments For Proceeds From Other Deposits PaymentsForProceedsFromOtherDeposits	-187500	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4500000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6361499	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	60000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	683194	USD
	rzlt	Increase Decrease In Deferred Lease Liability IncreaseDecreaseInDeferredLeaseLiability	-49950	USD
	rzlt	Increase Decrease In Deferred Lease Liability IncreaseDecreaseInDeferredLeaseLiability	-58924	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-146287	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-29153	USD
	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	-11462	USD
	us-gaap	Increase Decrease In Deferred Leasing Fees IncreaseDecreaseInDeferredLeasingFees	0	USD
	rzlt	Repayments Of Capital Lease Payable RepaymentsOfCapitalLeasePayable	0	USD
	rzlt	Repayments Of Capital Lease Payable RepaymentsOfCapitalLeasePayable	23128	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	18016	USD
	rzlt	Fair Value Of Financial Instruments Earnings FairValueOfFinancialInstrumentsEarnings	498	USD
CY2017Q4	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	90	USD
CY2017Q4	rzlt	Working Capital Deficit WorkingCapitalDeficit	1087141	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2519520	USD
CY2017	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	8100000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	186671	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4440000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	60000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	11090000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	255000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	457000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21088751	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9250001	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.08
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.65
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.65
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.09
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21290751	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.65
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8637760	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	33161041	shares
	rzlt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Expired In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExpiredInPeriod	285407	shares
	rzlt	Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice	2.43
CY2017Q4	rzlt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice	1.69
CY2017	rzlt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageRemainingContractualTerm	P3Y8M12D
	rzlt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageRemainingContractualTerm	P3Y2M12D
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32796448	shares
CY2017Q2	rzlt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice	1.71
	rzlt	Fair Value Of Warrants FairValueOfWarrants	90	USD
CY2017	rzlt	Fair Value Of Warrants FairValueOfWarrants	588	USD
CY2014Q2	us-gaap	Area Of Land AreaOfLand	27000	acre
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	28939	USD
CY2014Q2	rzlt	Payments Of Monthly Lease Adjusted Annually Percentage PaymentsOfMonthlyLeaseAdjustedAnnuallyPercentage	0.03	pure
CY2014Q2	rzlt	Adjusted Triple Net Expense Of Lease Payments AdjustedTripleNetExpenseOfLeasePayments	34381	USD
CY2014Q2	us-gaap	Security Deposit SecurityDeposit	750000	USD
CY2014Q2	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	375000	USD
CY2017Q4	rzlt	Operating Leases Future Minimum Payments Remainder Of Fiscal Year Gross OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYearGross	365680	USD
CY2017Q4	rzlt	Operating Leases Future Minimum Payments Due In Two Years Gross OperatingLeasesFutureMinimumPaymentsDueInTwoYearsGross	747953	USD
CY2017Q4	rzlt	Operating Leases Future Minimum Payments Due In Three Years Gross OperatingLeasesFutureMinimumPaymentsDueInThreeYearsGross	688892	USD
CY2017Q4	rzlt	Operating Leases Future Minimum Payments Due In Four Years Gross OperatingLeasesFutureMinimumPaymentsDueInFourYearsGross	338392	USD
CY2017Q4	rzlt	Operating Leases Future Minimum Payments Due In Five Years Gross OperatingLeasesFutureMinimumPaymentsDueInFiveYearsGross	347836	USD
CY2017Q4	rzlt	Operating Leases Future Minimum Payments Due Thereafter Gross OperatingLeasesFutureMinimumPaymentsDueThereafterGross	569364	USD
CY2017Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Remainder Of Fiscal Year FutureMinimumSubleaseRentalsSaleLeasebackTransactionsRemainderOfFiscalYear	76866	USD
CY2017Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Within Two Years FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears	157187	USD
CY2017Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Within Three Years FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears	148551	USD
CY2017Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Within Four Years FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears	0	USD
CY2017Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Within Five Years FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears	0	USD
CY2017Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Thereafter FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter	0	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	288814	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	590766	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	540341	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	338392	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	347836	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	569364	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10.5pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b><u> Note 1 Nature of Operations</u></b></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><b>  </b></font></div> <font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10.5pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif">These financial statements represent the consolidated financial statements of Rezolute, Inc. (“Rezolute”), and its wholly owned operating subsidiary AntriaBio Delaware, Inc. (“Antria Delaware”). Rezolute and Antria Delaware are collectively referred to herein as the “Company”. The Company is a clinical stage biopharmaceutical Company.</font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7311528	USD
CY2017Q4	us-gaap	Depreciation Depreciation	266781	USD
CY2016Q4	us-gaap	Depreciation Depreciation	278074	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	344669	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10.5pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong>Use of Estimates</strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif"> <strong> </strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10.5pt Times New Roman, Times, Serif" align="justify"><font style="FONT-SIZE: 10pt;FONT-FAMILY:Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: estimated useful lives and impairment of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54073309	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49228640	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54073309	shares
CY2017Q2	us-gaap	Financial Instruments Owned At Fair Value FinancialInstrumentsOwnedAtFairValue	588	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7317343	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.84	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3413088	USD
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3075379	USD
CY2017Q4	rzlt	Operating Leases Future Minimum Payments Due Gross OperatingLeasesFutureMinimumPaymentsDueGross	3058117	USD
CY2017Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions FutureMinimumSubleaseRentalsSaleLeasebackTransactions	382604	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2675513	USD
	rzlt	Compensation And Benefits For Research And Development CompensationAndBenefitsForResearchAndDevelopment	2983810	USD
	rzlt	Compensation And Benefits For Research And Development CompensationAndBenefitsForResearchAndDevelopment	3213358	USD
	rzlt	Consultants And Outside Costs ConsultantsAndOutsideCosts	364159	USD
	rzlt	Consultants And Outside Costs ConsultantsAndOutsideCosts	466258	USD
	us-gaap	Manufacturing Costs ManufacturingCosts	653691	USD
	us-gaap	Manufacturing Costs ManufacturingCosts	1079137	USD
	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1561754	USD
	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	0	USD
	us-gaap	License Costs LicenseCosts	1178505	USD
	us-gaap	License Costs LicenseCosts	0	USD
	rzlt	Facilities And Other Costs FacilitiesAndOtherCosts	981807	USD
	rzlt	Facilities And Other Costs FacilitiesAndOtherCosts	802555	USD
	rzlt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued For Consulting Services ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssuedForConsultingServices	650000	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7723726	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5561308	USD
	rzlt	Compensation And Benefits For General And Administrative CompensationAndBenefitsForGeneralAndAdministrative	3467921	USD
	rzlt	Compensation And Benefits For General And Administrative CompensationAndBenefitsForGeneralAndAdministrative	2151953	USD
	us-gaap	Professional Fees ProfessionalFees	436993	USD
	rzlt	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price Warrants Issued For Consulting Services ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePriceWarrantsIssuedForConsultingServices	1.03
	rzlt	Investor Relations InvestorRelations	193576	USD
	rzlt	Investor Relations InvestorRelations	155535	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	645872	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	558115	USD
CY2017Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2337870	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4744362	USD
	us-gaap	Operating Expenses OperatingExpenses	12468088	USD
	us-gaap	Operating Expenses OperatingExpenses	8712927	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12468088	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8712927	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	861	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	63676	USD
	us-gaap	Rental Income Nonoperating RentalIncomeNonoperating	0	USD
	us-gaap	Interest Expense InterestExpense	147	USD
	us-gaap	Interest Expense InterestExpense	1595	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	498	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	10725	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	64888	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9130	USD
	rzlt	Conversionofconvertiblenotespayabletocommonstock Conversionofconvertiblenotespayabletocommonstock	0	USD
	rzlt	Conversionofconvertiblenotespayabletocommonstock Conversionofconvertiblenotespayabletocommonstock	50000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12403200	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53327558	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38091406	shares
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	USD
	rzlt	Warrant Value Recorded As Issuance Cost WarrantValueRecordedAsIssuanceCost	0	USD
	rzlt	Warrant Value Recorded As Issuance Cost WarrantValueRecordedAsIssuanceCost	516550	USD
	rzlt	Warrantvaluerecordedasdebtdiscount Warrantvaluerecordedasdebtdiscount	0	USD
	rzlt	Warrantvaluerecordedasdebtdiscount Warrantvaluerecordedasdebtdiscount	9517	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	469177	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	12097	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-2800	USD
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1813865	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	317674	USD
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure

Files In Submission

Name	View Source	Status
0001144204-18-008930-index-headers.html	Edgar Link	pending
0001144204-18-008930-index.html	Edgar Link	pending
0001144204-18-008930.txt	Edgar Link	pending
0001144204-18-008930-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rzlt-20171231.xml	Edgar Link	completed
rzlt-20171231.xsd	Edgar Link	pending
rzlt-20171231_cal.xml	Edgar Link	unprocessable
rzlt-20171231_def.xml	Edgar Link	unprocessable
rzlt-20171231_lab.xml	Edgar Link	unprocessable
rzlt-20171231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
tv484281_10q.htm	Edgar Link	pending
tv484281_ex10-1.htm	Edgar Link	pending
tv484281_ex10-2.htm	Edgar Link	pending
tv484281_ex31-1.htm	Edgar Link	pending
tv484281_ex31-2.htm	Edgar Link	pending
tv484281_ex32-1.htm	Edgar Link	pending
tv484281_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RZLT
Rezolute, Inc. Stock $rzlt

2018 Q1 Form 10-Q Financial Statement

#000114420418008930 Filed on February 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RZLT Rezolute, Inc. Stock $rzlt

2018 Q1 Form 10-Q Financial Statement

#000114420418008930 Filed on February 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RZLT
Rezolute, Inc. Stock $rzlt